Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights
May 08, 2024 06:45 ET
|
Compass Pathways
COMP360 phase 3 pivotal program in treatment-resistant depression (TRD) on track for top-line COMP005 trial data in fourth quarter 2024, COMP006 trial top-line data expected mid-2025Compass announces...
AvidXchange Announces First Quarter 2024 Financial Results
May 08, 2024 06:45 ET
|
AvidXchange
Q1 2024 Earnings Release
Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day
May 08, 2024 06:40 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program
May 08, 2024 06:30 ET
|
Veru Inc.
--Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy®*) for high quality weight loss is actively enrolling-- --Company assembles esteemed high quality weight loss Scientific...
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
May 08, 2024 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
May 08, 2024 06:30 ET
|
Compass Pathways
Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed Early and clinically meaningful improvement from baseline in mean CAPS-5 total score (29.5...
Taboola Q1 2024 Results Beat High End of Guidance; Reiterates 2024 Guidance and Expects Accelerating Growth Across All Key Metrics
May 08, 2024 06:15 ET
|
Taboola, Inc.
Q1 2024 and FY 2024 Key HighlightsQ1 Financials - beat high end of guidance across all key metrics Q1 2024 Revenues $414M, Gross profit $109M, ex-TAC Gross Profit $139M, Net loss $26M,...
Qifu Technology to Hold Annual General Meeting on June 27, 2024
May 08, 2024 06:01 ET
|
Qifu Technology, Inc.
SHANGHAI, China, May 08, 2024 (GLOBE NEWSWIRE) -- Qifu Technology, Inc. (NASDAQ: QFIN; HKEx: 3660) (“Qifu Technology” or the “Company”), a leading Credit-Tech platform in China, today announced that...
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
May 08, 2024 06:00 ET
|
Regeneron Pharmaceuticals, Inc.
Preliminary data detailed in an ASGCT oral presentation include results for one of the youngest children in the world to receive a gene therapy for genetic deafness Ongoing Phase 1/2 CHORD trial is...
Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
May 08, 2024 06:00 ET
|
Voyager Therapeutics, Inc.
- Translational potential of TRACER-derived AAV capsids demonstrated by data across multiple species (murine, porcine, multiple NHPs, human cells) and receptor binding - - Preclinical safety and...